生物医学および薬学ジャーナル

A Clinical Report on the Safety and Successful Application of Tocilizumab in Rheumatoid Arthritis Patients Receiving Continuous Haemodialysis Treatment

Abstract

Daniel Mikos

Rheumatoid Arthritis (RA) is a chronic autoimmune disorder characterized by joint inflammation and damage. Tocilizumab, an interleukin-6 receptor inhibitor, has emerged as a promising treatment for RA. However, concerns exist about its safety and effectiveness in patients undergoing continuous haemodialysis treatment. This clinical report presents a comprehensive analysis of the safety and successful application of Tocilizumab in RA patients on continuous haemodialysis.